Biocept Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Biocept wird ein Gewinn- und Umsatzwachstum von 56.6% bzw. 67.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 77.3% pro Jahr wachsen soll.

Wichtige Informationen

56.6%

Wachstumsrate der Gewinne

77.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	67.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BIOC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	21	-17	N/A	N/A	1
12/31/2024	6	-23	N/A	N/A	1
12/31/2023	2	-22	N/A	N/A	1
6/30/2023	1	-31	-18	-18	N/A
3/31/2023	7	-37	-19	-19	N/A
12/31/2022	26	-32	-14	-13	N/A
9/30/2022	41	-25	-9	-7	N/A
6/30/2022	57	-16	-5	-4	N/A
3/31/2022	63	-8	1	2	N/A
12/31/2021	61	-3	2	4	N/A
9/30/2021	66	2	-1	1	N/A
6/30/2021	55	-2	-7	-5	N/A
3/31/2021	44	-7	-15	-14	N/A
12/31/2020	27	-18	-21	-20	N/A
9/30/2020	11	-25	-25	-24	N/A
6/30/2020	6	-26	-24	-23	N/A
3/31/2020	6	-28	-24	-23	N/A
12/31/2019	6	-25	-24	-23	N/A
9/30/2019	5	-26	-23	-23	N/A
6/30/2019	4	-27	-23	-23	N/A
3/31/2019	3	-25	-22	-22	N/A
12/31/2018	3	-25	-23	-22	N/A
9/30/2018	3	-25	-23	-23	N/A
6/30/2018	4	-24	-23	-22	N/A
3/31/2018	4	-24	-23	-21	N/A
12/31/2017	5	-22	-21	-20	N/A
9/30/2017	5	-20	-19	-18	N/A
6/30/2017	5	-19	-17	-16	N/A
3/31/2017	5	-18	N/A	-15	N/A
12/31/2016	3	-18	N/A	-16	N/A
9/30/2016	2	-19	N/A	-16	N/A
6/30/2016	1	-19	N/A	-16	N/A
3/31/2016	1	-18	N/A	-16	N/A
12/31/2015	1	-17	N/A	-15	N/A
9/30/2015	0	-16	N/A	-14	N/A
6/30/2015	0	-16	N/A	-14	N/A
3/31/2015	0	-15	N/A	-13	N/A
12/31/2014	0	-16	N/A	-15	N/A
9/30/2014	0	-14	N/A	-13	N/A
6/30/2014	0	-13	N/A	-11	N/A
3/31/2014	0	-12	N/A	-10	N/A
12/31/2013	0	-9	N/A	-6	N/A
9/30/2013	0	-10	N/A	-7	N/A
6/30/2013	0	-10	N/A	-7	N/A
3/31/2013	0	-11	N/A	-8	N/A
12/31/2012	0	-12	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIOC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BIOC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BIOC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BIOCDie Einnahmen des Unternehmens (67.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: BIOCDie Einnahmen des Unternehmens (67.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BIOC in 3 Jahren voraussichtlich hoch sein wird

Biocept Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

Consensus revenue estimates increase to US$37.5m

Price target decreased to US$12.00

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

No longer forecast to breakeven

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Investor sentiment improved over the past week

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Consensus revenue estimates increase to US$37.5m

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Price target decreased to US$12.00

Biocept enters COVID-19 testing partnership

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: US$6.70

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

New 90-day high: US$6.23

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Analysts update estimates

Biocept +4% on COVID-19 testing update

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

Analysts update estimates

Price target raised to US$2.03

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance